Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
May 05 2022 - 7:00AM
Business Wire
ADI-001 exhibited robust in vitro and in vivo
tumor growth inhibition in multiple human lymphoma cell lines, with
adaptive and innate mechanisms contributing to its anti-tumor
activity
Non-gene-edited ADI-001 gamma delta CAR T cells
demonstrated superior resilience to host versus graft targeting
when compared to common gene-edited approaches
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing first-in-class allogeneic gamma
delta chimeric antigen receptor (CAR) T cell therapies for cancer,
today announced data from a preclinical evaluation of ADI-001 at
the International Society for Cell and Gene Therapy (ISCT) Annual
Meeting taking place in San Francisco, May 4-7, 2022. ADI-001 is
currently being evaluated in an ongoing dose escalation Phase 1
study evaluating the safety and tolerability of ADI-001 for the
potential treatment of relapsed or refractory B-cell Non-Hodgkin’s
lymphoma (NHL).
The extensive preclinical evaluation reported at ISCT observed
that ADI-001 exhibited a predominantly naïve-like T cell memory
phenotype, expressed multiple chemokine and innate-activating cell
receptors and exhibited robust in vitro and in vivo tumor growth
inhibition against multiple human lymphoma cell lines, with
adaptive and innate activation pathways contributing to the
anti-tumor activity of ADI-001.
Susceptibility to host versus graft targeting was also evaluated
using mixed-lymphocyte reactions incorporating up to 13 different
allogeneic lymphocyte samples. Non-gene-edited ADI-001 gamma delta
CAR T cells demonstrated high levels of endogenous HLA-E expression
in the unmodified state and were associated with superior
resilience to lymphocyte-mediated clearance when compared to
approaches commonly deployed in gene-edited allogeneic cell therapy
platforms (β2MKO with or without HLA-E overexpression).
“In this first view comparing Adicet’s non-gene-edited gamma
delta CAR T cells to alternative and popularly-reported gene
editing strategies, we appreciate the lower preclinical
susceptibility to host versus graft targeting demonstrated by
non-gene-edited ADI-001,” said Blake Aftab, Ph.D., Chief Scientific
Officer at Adicet. “Together, the results of this extended
characterization highlight potential advantages of our allogeneic
gamma delta T cell platform, with adaptive and innate mechanisms
contributing to the anti-tumor activity of ADI-001.”
Poster Presentation Details
Title: Evaluation of non-gene edited allogeneic
“off-the-shelf” Vδ1 γδ (gamma delta) CAR T cells targeting CD20 for
B cell malignancies
ePoster Presentation: Thursday, May 5 at 4:00 p.m. PT
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with CAR and T cell receptor-like
targeting moieties to enhance selective tumor targeting, facilitate
innate and adaptive anti-tumor immune response, and improve
persistence for durable activity in patients. For more information,
please visit our website at http://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to business and operations of Adicet.
These forward-looking statements include, but are not limited to,
express or implied statements regarding data from the preclinical
evaluation of ADI-001, including Adicet’s beliefs and expectations
regarding the potential therapeutic effects, design and success of
ADI-001.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements,
including without limitation, the effect of COVID-19 on Adicet’s
business and financial results, including with respect to
disruptions to Adicet’s preclinical evaluations and clinical
trials, business operations, and ability to raise additional
capital; Adicet's ability to execute on its strategy; that positive
results from a preclinical or clinical study may not necessarily be
predictive of the results of future or ongoing studies; future
preclinical or clinical studies may fail to demonstrate adequate
safety and efficacy of Adicet’s product candidates, which would
prevent, delay, or limit the scope of regulatory approval and
commercialization; regulatory approval processes of the FDA and
comparable foreign regulatory authorities are lengthy,
time-consuming, and inherently unpredictable; and regulatory
developments in the United States and foreign countries. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Adicet's actual results
to differ from those contained in the forward-looking statements,
see the section entitled "Risk Factors" in Adicet's most recent
Annual Report on Form 10-K for the year ended December 31, 2021 as
filed with the U.S. Securities and Exchange Commission (SEC) and
subsequent filings with the SEC, as well as discussions of
potential risks, uncertainties, and other important factors in
Adicet's other filings with the SEC. All information in this press
release is as of the date of the release, and Adicet undertakes no
duty to update this information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220505005373/en/
Adicet Bio Inc. Media and Investor Contacts:
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jul 2023 to Jul 2024